| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 5.094 | 40.023 | 36.663 | 43.909 | 34.849 |
| Total Income - EUR | - | - | - | - | - | 5.094 | 40.026 | 36.673 | 43.917 | 34.860 |
| Total Expenses - EUR | - | - | - | - | - | 1.338 | 8.644 | 13.135 | 18.890 | 25.523 |
| Gross Profit/Loss - EUR | - | - | - | - | - | 3.756 | 31.383 | 23.538 | 25.027 | 9.337 |
| Net Profit/Loss - EUR | - | - | - | - | - | 3.636 | 30.563 | 23.200 | 24.654 | 8.039 |
| Employees | - | - | - | - | - | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Topostoma-Biovet S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 0 | 5.963 | 5.435 | 9.875 | 6.684 |
| Current Assets | - | - | - | - | - | 4.397 | 30.439 | 23.667 | 42.888 | 8.464 |
| Inventories | - | - | - | - | - | 670 | 3.870 | 5.605 | 7.676 | 654 |
| Receivables | - | - | - | - | - | 0 | 3.789 | 559 | 479 | 2.557 |
| Cash | - | - | - | - | - | 3.728 | 22.780 | 17.503 | 34.733 | 5.252 |
| Shareholders Funds | - | - | - | - | - | 3.677 | 34.159 | 22.246 | 40.767 | 5.357 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 720 | 2.243 | 6.856 | 11.996 | 9.791 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Topostoma-Biovet S.r.l.